Piloting New Medications for Borderline Personality Disorder: The Use of Artificial Intelligence in Psychopharmacological Research
Psychopharmacology Bulletin · 29.10.2026 · 56 (4) · 26-40
DOI: 10.64719/pb.21597 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychopharmacology Bulletin, online erschienen am 29.10.2026. Verfasst von Carlo Lazzari und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lazzari, Department of Molecular Psychopharmacology, International Centre for Healthcare and Medical Education, London, United Kingdom. Hauptthemen laut MEDLINE: Borderline Personality Disorder, Artificial Intelligence, Drug Discovery. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Borderline Personality Disorder (BPD) lacks approved pharmacological treatments despite a high symptom burden. Artificial intelligence (AI) offers new opportunities to accelerate drug discovery and model therapeutic effects.
Objective
This study will outline an AI-enabled framework for identifying and modelling a novel pharmacological agent for BPD, designed to meet five therapeutic goals: (1) reduce depression without increasing impulsivity and suicidality, (2) reduce suicidality without sedation, (3) limit side effects and weight gain, (4) reduce polypharmacy, and (5) provide combined antidepressant, anti-suicidal, mood-stabilising, and antipsychotic effects.
Methods
Three AI-driven approaches will be piloted: (1) deep-learning-based compound generation, (2) natural-language-processing (NLP) evidence synthesis, and (3) predictive modelling of symptom trajectories. These methods will be used to design and characterise a hypothetical multimodal compound, BPD-AI-01, including its predicted 3D molecular structure and receptor binding profile. All analyses will use publicly available data and in silico simulations.
Results
AI-guided modelling will generate BPD-AI-01, a candidate molecule predicted to act as a partial agonist at 5-HT1A receptors, a modulator at NMDA-associated sites, and a weak antagonist at 5-HT2A/D2 receptors, with low affinity for histaminergic and muscarinic receptors. Its 3D structure will be optimised to balance CNS penetration with reduced metabolic burden. Simulated trajectories will suggest potential antidepressant, anti-suicidal, mood-stabilising, and antipsychotic-like effects without marked sedation or weight gain.
Conclusions
AI-enabled pharmacological research may support the design of next-generation medications for BPD that address multiple symptom domains within a single molecule. Empirical validation will be required before any clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lazzari, Department of Molecular Psychopharmacology, International Centre for Healthcare and Medical Education, London, United Kingdom.
- Rabottini, Department of Molecular Psychopharmacology, International Centre for Healthcare and Medical Education, London, United Kingdom.
Zitieren
APA
Lazzari, C., & Rabottini, M. (2026). Piloting New Medications for Borderline Personality Disorder: The Use of Artificial Intelligence in Psychopharmacological Research. Psychopharmacology Bulletin, 56(4), 26-40. https://doi.org/10.64719/pb.21597
Vancouver
Lazzari C, Rabottini M. Piloting New Medications for Borderline Personality Disorder: The Use of Artificial Intelligence in Psychopharmacological Research. Psychopharmacology Bulletin. 2026;56(4):26-40. doi:10.64719/pb.21597
BibTeX
@article{Lazzari2026,
author = {Lazzari, Carlo and Rabottini, Marco},
title = {Piloting New Medications for Borderline Personality Disorder: The Use of Artificial Intelligence in Psychopharmacological Research},
journal = {Psychopharmacology Bulletin},
year = {2026},
volume = {56},
number = {4},
pages = {26--40},
doi = {10.64719/pb.21597}
}
EUVIMED